- Conditions
- Endometriosis
- Interventions
- Elagolix
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–23
of 23
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Endometriosis
- Interventions
- Estradiol/Norethindrone Acetate, Placebo for Elagolix, Elagolix, Placebo for E2/NETA
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 681 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 188
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 140 more
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroids
- Interventions
- Not listed
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Cerebrovascular Disorders
- Interventions
- Indomethacin, Placebo, Orilissa, Testosterone gel, Anastrozole, Estradiol
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Uterine Fibroids
- Interventions
- Elagolix, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Searcy, Arkansas • La Mesa, California + 35 more
- Conditions
- Endometriosis
- Interventions
- BAY1817080, Elagolix, Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 36 more
- Conditions
- Uterine Fibroids, Heavy Menstrual Bleeding
- Interventions
- Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 89 more
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Elagolix, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Mobile, Alabama • San Diego, California + 43 more
- Conditions
- Endometriosis
- Interventions
- elagolix, estradiol/norethindrone acetate (E2/NETA)
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 37
- States / cities
- Anniston, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
- Conditions
- Uterine Fibroids, Heavy Menstrual Bleeding
- Interventions
- Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 92
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Costa Mesa, California + 79 more
- Conditions
- Endometriosis, Uterine Fibrioids
- Interventions
- Not listed
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- Female only
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Endometriosis, Unexplained Infertility
- Interventions
- Elagolix, Ortho Cyclen
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 42 Years · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Endometriosis
- Interventions
- Elagolix, Placebo, Combined Oral Contraceptive
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 176
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 134 more
- Conditions
- Folliculogenesis
- Interventions
- elagolix
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 216 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 20
- States / cities
- Colorado Springs, Colorado • Denver, Colorado • Lonetree, Colorado + 14 more
- Conditions
- Infertility, Endometriosis
- Interventions
- Elagolix 200 MG, Leuprolide Acetate 3.75 MG/ML, Lab work
- Drug · Diagnostic Test
- Lead sponsor
- Colorado Center for Reproductive Medicine
- Other
- Eligibility
- 21 Years to 42 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Lone Tree, Colorado
- Conditions
- Uterine Fibroids, Heavy Menstrual Bleeding
- Interventions
- Estradiol/Norethindrone Acetate, Elagolix
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 433 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 90 more
- Conditions
- Mild Autonomous Cortisol Excess
- Interventions
- Elagolix
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Uterine Fibroids (UF)
- Interventions
- Not listed
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Arlington, Virginia
- Conditions
- Infertility, Endometriosis
- Interventions
- Elagolix 200 MG, Placebo or SOC IVF
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Chicago, Illinois + 2 more
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroids
- Interventions
- Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo, Elagolix Placebo
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 155
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 112 more
- Conditions
- Heavy Menstrual Bleeding, Fibroid Uterus
- Interventions
- Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure, Elagolix Oral Product
- Other · Drug
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Menopause, Aging
- Interventions
- Elagolix Oral Tablet, Estradiol patch, cellulose placebo, placebo patch
- Drug · Other
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 42 Years to 64 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Infertility, Endometriosis
- Interventions
- Elagolix 200 MG, Placebo or SOC IVF
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Chicago, Illinois + 2 more